【摘要】 目的 觀察鹽酸氨基葡萄糖治療腰椎關節突關節骨性關節炎（lumbar zygapophyseal joint osteoarthritis，LZOA）的臨床療效及安全性。 方法 2009年1月-2010年1月，對90例LZOA患者隨機分成治療組和對照組，各45例。治療組口服鹽酸氨基葡萄糖，6周為1個療程，治療3個療程，前2周均加用洛索洛芬鈉；對照組患者僅給予洛索洛芬鈉口服12周。比較兩組治療后2、6周及3、6、12個月的療效及安全性。 結果 治療后6周、3個月，治療組與對照組癥狀均明顯改善，對照組改善更明顯。治療6個月后，治療組評分持續下降，到12個月時與治療前比較差異有統計學意義（Plt;0.01）；而對照組評分則逐漸增高，到12個月時與其治療前比較差異無統計學意義（Pgt;0.05）。兩組的不良反應率分別為6.67%、15.56%，差異有統計學意義（Plt;0.01）。 結論 鹽酸氨基葡萄糖治療LZOA療效確切，且安全性良好。【Abstract】 Objective To observe the clinical efficacy and safety of glucosamine hydrochloride on lumbar zygapophyseal joint osteoarthritis (LZOA). Methods From January 2009 to January 2010, 90 patients with LZOA were randomly divided into therapeutic group and comparative group, with 45 patients in each group. Patients in therapeutic group were treated with oral administration of glucosamine hydrochloride for 3 courses (6 weeks for one course; adding loxoprofen for the early 2 weeks). Patients in comparative group were treated with oral administration of loxoprofen for 12 weeks. The efficacy and safety between the two groups was compared. Results Symptoms in both group were relieved after 6-week and 3-month treatment. More obvious relief was observed in the comparative group. The scoring of therapeutic group kept decreasing after 6-month treatment. The efficacy showed significant improvement after 12-month treatment compared with which before the treatment was significant（Plt;0.01）. The scoring in comparative group kept increasing, which showed no significant difference after 12-month treatment（Pgt;0.05）. The adverse effect rate was 6.67% and 15.56% respectively in two groups, which was significant different（Plt;0.01）. Conclusions Glucosamine hydrochloride provides good efficacy and safety for patients with LZOA.
